ALKERMES PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.63 USD | -0.55% |
|
-3.07% | -14.67% |
| Apr. 09 | Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday | MT |
| Apr. 09 | Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study | MT |
Financials (USD)
| Sales 2024 * | 1.52B | Sales 2025 * | 1.53B | Capitalization | 4.02B |
|---|---|---|---|---|---|
| Net income 2024 * | 348M | Net income 2025 * | 340M | EV / Sales 2024 * | 2.13 x |
| Net cash position 2024 * | 791M | Net cash position 2025 * | 1.17B | EV / Sales 2025 * | 1.86 x |
| P/E ratio 2024 * |
11.7
x | P/E ratio 2025 * |
12.4
x | Employees | 2,100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alkermes plc
More recommendations
More press releases
| 1 day | -1.00% | ||
| 1 week | -4.88% | ||
| Current month | -12.19% | ||
| 1 month | -13.66% | ||
| 3 months | -14.37% | ||
| 6 months | -12.55% | ||
| Current year | -14.31% |
1 week
23.62
24.64
1 month
23.6227.99
Current year
23.6232.88
1 year
22.0133.71
3 years
19.9233.71
5 years
11.9834.97
10 years
11.9880.71
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 62 | 91-01-31 |
Blair Jackson
DFI | Director of Finance/CFO | 51 | 98-12-31 |
Shane Cooke
PSD | President | 61 | 11-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 62 | 91-01-31 |
Nancy Snyderman
BRD | Director/Board Member | 72 | 16-05-25 |
Brian McKeon
BRD | Director/Board Member | 61 | 20-12-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 15.32% | 215 M€ | +12.86% | - | |
| 2.65% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 23.65 | -0.46% | 123 512 |
| 24-04-18 | 23.76 | -1.04% | 1,798,839 |
| 24-04-17 | 24.01 | +1.01% | 2,257,028 |
| 24-04-16 | 23.77 | -1.04% | 1,579,931 |
| 24-04-15 | 24.02 | -1.64% | 2,713,260 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
23.76
USD
Average target price
35.25
USD
Spread / Average Target
+48.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.31% | 4.02B | |
| -1.82% | 41.35B | |
| +42.04% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- ALKS Stock
